EA200702191A1 - Новая полиморфная форма кристаллической гемикальциевой соли аторвастатина - Google Patents

Новая полиморфная форма кристаллической гемикальциевой соли аторвастатина

Info

Publication number
EA200702191A1
EA200702191A1 EA200702191A EA200702191A EA200702191A1 EA 200702191 A1 EA200702191 A1 EA 200702191A1 EA 200702191 A EA200702191 A EA 200702191A EA 200702191 A EA200702191 A EA 200702191A EA 200702191 A1 EA200702191 A1 EA 200702191A1
Authority
EA
Eurasian Patent Office
Prior art keywords
polymorphic form
new polymorphic
atorvastatin
salt
hemicaltie
Prior art date
Application number
EA200702191A
Other languages
English (en)
Other versions
EA014079B1 (ru
Inventor
Йожеф Баркоци
Петер Котай Надь
Дьюла Шимиг
Юдит Челеньяк
Жужанна Сент-Кираллии
Ференц Барта
Зольтан Катона
Дьёрди Верецкеине Донат
Кальман Надь
Норберт Немет
Дьёрдь Ружич
Original Assignee
Эгиш Дьёдьсердьяр Ньильваношан Мюкёдё Ресвеньтаршашаг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from HU0500370A external-priority patent/HU0500370D0/hu
Priority claimed from HU0600120A external-priority patent/HUP0600120A3/hu
Application filed by Эгиш Дьёдьсердьяр Ньильваношан Мюкёдё Ресвеньтаршашаг filed Critical Эгиш Дьёдьсердьяр Ньильваношан Мюкёдё Ресвеньтаршашаг
Publication of EA200702191A1 publication Critical patent/EA200702191A1/ru
Publication of EA014079B1 publication Critical patent/EA014079B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Настоящее изобретение относится к новой полиморфной форме В-52 кристаллической гемикальциевой соли аторвастатина [кальциевая соль (3R,5R)-7-[3-фенил-4-[(фенилкарбамоил]-2-(4-фторфенил)-5-(1-метилэтил)-1Н-пиррол-1-ил]-3,5-дигидроксигептановой кислоты (2:1)], лекарственным препаратам, содержащим новую полиморфную форму, способу ее получения и применению новой полиморфной формы для получения лекарственных продуктов.
EA200702191A 2005-04-08 2006-04-07 Новая полиморфная форма кристаллической гемикальциевой соли аторвастатина EA014079B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU0500370A HU0500370D0 (en) 2005-04-08 2005-04-08 New crystalline atorvastatin hemicalcium polimorph
HU0600120A HUP0600120A3 (en) 2006-02-14 2006-02-14 New crystalline atorvastatin hemicalcium, pharmaceutical composition containing it and process for producing it
PCT/HU2006/000026 WO2006106372A1 (en) 2005-04-08 2006-04-07 New crystalline atorvastatin hemicalcium salt polymorph form

Publications (2)

Publication Number Publication Date
EA200702191A1 true EA200702191A1 (ru) 2008-04-28
EA014079B1 EA014079B1 (ru) 2010-08-30

Family

ID=89986585

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200702191A EA014079B1 (ru) 2005-04-08 2006-04-07 Новая полиморфная форма кристаллической гемикальциевой соли аторвастатина

Country Status (13)

Country Link
US (1) US20090215855A1 (ru)
EP (1) EP1868993B1 (ru)
JP (1) JP5523699B2 (ru)
BG (1) BG66035B1 (ru)
CZ (1) CZ2007772A3 (ru)
EA (1) EA014079B1 (ru)
HK (1) HK1117141A1 (ru)
IL (1) IL186499A (ru)
NO (1) NO20075721L (ru)
RO (1) RO200700700A8 (ru)
RU (1) RU2409563C2 (ru)
SK (1) SK288276B6 (ru)
WO (1) WO2006106372A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8080672B2 (en) 2005-12-13 2011-12-20 Teva Pharmaceutical Industries Ltd. Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
US20090240064A1 (en) * 2006-02-22 2009-09-24 Venkata Panakala Rao Gogulapati Crystalline form of atorvastatin hemi-calcium
US20120244220A1 (en) * 2009-12-25 2012-09-27 Sawai Pharmaceutical Co., Ltd. Atrovastatin-containing coated preparation
KR20120011249A (ko) * 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5003080A (en) * 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
PL193479B1 (pl) * 1995-07-17 2007-02-28 Warner Lambert Co Formy krystaliczne hydratu atorwastatyny, kompozycja farmaceutyczna zawierająca formę krystaliczną I hydratu atorwastatyny oraz jej zastosowanie
CA2426632C (en) * 2000-11-03 2008-08-05 Teva Pharmaceutical Industries, Ltd. Atorvastatin hemi-calcium form vii
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
CA2626317A1 (en) * 2000-12-27 2002-07-04 Teva Pharmaceutical Industries Ltd. Crystalline forms of atorvastatin
PL372303A1 (en) * 2002-02-15 2005-07-11 Teva Pharmaceutical Industries Ltd. Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix
CA2475123A1 (en) * 2002-02-19 2003-08-28 Teva Pharmaceutical Industries Ltd. Desolvating solvates of atorvastatin hemi-calcium

Also Published As

Publication number Publication date
US20090215855A1 (en) 2009-08-27
JP2008534669A (ja) 2008-08-28
IL186499A0 (en) 2008-01-20
JP5523699B2 (ja) 2014-06-18
RU2409563C2 (ru) 2011-01-20
RU2007140797A (ru) 2009-05-20
NO20075721L (no) 2008-01-04
EP1868993A1 (en) 2007-12-26
CZ2007772A3 (cs) 2008-02-27
EP1868993B1 (en) 2014-04-30
HK1117141A1 (en) 2009-01-09
WO2006106372A1 (en) 2006-10-12
SK288276B6 (sk) 2015-06-02
IL186499A (en) 2016-04-21
WO2006106372A8 (en) 2008-03-13
SK51252007A3 (sk) 2008-07-07
BG109992A (bg) 2008-05-30
RO123642B1 (ro) 2015-07-30
RO200700700A8 (ro) 2015-07-30
EA014079B1 (ru) 2010-08-30
BG66035B1 (bg) 2010-11-30

Similar Documents

Publication Publication Date Title
PL396343A1 (pl) Preparat farmaceutyczny zawierający sól wapniową atorwarstatyny, sposób wytwarzania tego preparatu i jego zastosowanie do leczenia hipercholesterolemii i hiperlipidemii
HUP9901687A2 (hu) Kristályos (III) formájú (R-(R*,R*)-2-(4-fluor-fenil)-béta,delta-dihidroxi-5-(1-metil-etil)-3-fenil-4-((fenil-amino)-karbonil)-1H-pirrol-1-heptánsav hemi kálcium-só (Atorvastatin) és ezt a vegyületet tartalmazó gyógyszerkészítmények
HUP0301325A2 (hu) Stabilizált, gyógyászatilag hatékony kompozíció és ezt tartalmazó gyógyszerkészítmény és eljárás a kompozíció előállítására
YU56803A (sh) Pripremanje nekristalinskog atorvastatin-kalcijuma
EA200301243A1 (ru) Кристаллические формы [r-(r*,r*)]-2-(4-фторфенил)-бета, дельта-дигидрокси-5-(1-метилэтил)-3-фенил-4-[(фениламино) карбонил]-1h-пиррол-1-гептановой кислоты кальциевой соли (2:1) (аторвастатин)
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
YU36802A (sh) Postupak za dobijanje amorfnog atorvastatina
AR003458A1 (es) Forma cristalina de atorvastatina o hidrato de la misma y composicion farmaceutica que la comprende.
BRPI0517567A (pt) composto ou um sal, solvato, ou derivado fisiologicamente funcional farmaceuticamente aceitável do mesmo, composição farmacêutica, usos de um composto ou um sal, solvato, ou derivado fisiologicamente funcional farmaceuticamente aceitável do mesmo e de uma composição farmacêutica, e, processo para preparar um composto
EP2682387A3 (en) C7-fluoro substituted tetracycline compounds
HUP0402590A3 (en) Method of manufacturing an amorphous form of the hemi-calcium salt of (3r,5r)7-3-phenyl-4-phenylcarbomoyl-2-(4-fluorophenyl)-5-isopropyl-pyrrol-1-yl!-3, 5-dihydroxyheptanoic acid (atorvastatin)
EA200702191A1 (ru) Новая полиморфная форма кристаллической гемикальциевой соли аторвастатина
NZ603207A (en) Combination of hmg-coa reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases
CY1112702T1 (el) Βελτιωμενη φαρμακευτικη συνθεση που περιεχει εναν αντισπασμωδικο παραγοντα πυρρολιδονης και μεθοδος για την παρασκευη της
DE602006019710D1 (de) Magnesiumsalze von hmg-coa-reduktase-hemmern
WO2004050618A3 (en) Crystalline form f of atorvastatin hemi-calcium salt
TW200738624A (en) Novel forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium
UA93202C2 (ru) Полиморфная форма кристаллической гемикальциевой соли аторвастатина
WO2009007856A3 (en) Novel polymorph of atorvastatin calcium and use thereof for the preparation of amorphous atorvastatin calcium
WO2006011041A3 (en) Crystalline forms of (r-(r*))-2-(4-fluorophenyl)-beta, gamma-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1-hept anoic acid calcium salt (2:1)
WO2010038948A3 (en) Arylpiperazine-containing pyrrole 3-carboxamide derivatives for treating depressive disorders
EA200901205A1 (ru) Фармацевтическая композиция, содержащая соль розиглитазона
EA200400391A1 (ru) Полиморфные формы производного 1-пиррола, промежуточного соединения для получения аторвастатина
WO2009000286A8 (en) Improved pharmaceutical formulation containing an hmg-coa reductase inhibitor and method for the preparation thereof
WO2009054693A3 (en) Process for the preparation of atorvastatin

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU